Postmenopausal hormone therapy is widely used to prevent diseases. This is
not, however, based on the kind of evidence that is normally required of a
preventive drug therapy: it is based on intermediary outcomes of trials and
non-experimental studies. Many reasons can be postulated for the fact that
we know little of this old and widely used therapy. To remedy the current
situation, we should encourage randomised controlled trials, reveal the ins
ufficiency of the current evidence, and challenge the drug industry's biase
d influence.